Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy - Archive ouverte HAL Access content directly
Journal Articles Science Advances Year : 2022

Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy

(1) , (1) , , (2) , (3) , , , , , (1) , (2, 1) , , (1) , (1)
1
2
3
Virginie Mutez
Nicolas Chuvin
Emilie Michel
Rasha Boulos
Yann Estornes
Qing Wang

Abstract

Human endogenous retroviruses (HERVs) represent 8% of the human genome. HERV products may represent tumor antigens relevant for cancer immunotherapy. We developed a bioinformatic approach to identify shared CD8 + T cell epitopes derived from cancer-associated HERVs in solid tumors. Six candidates among the most commonly shared HLA-A2 epitopes with evidence of translation were selected for immunological evaluation. In vitro priming assays confirmed the immunogenicity of these epitopes, which induced high-avidity CD8 + T cell clones. These T cells specifically recognize and kill HLA-A2 + tumor cells presenting HERV epitopes on HLA molecules, as demonstrated by mass spectrometry. Furthermore, epitope-specific CD8 + T cells were identified by dextramer staining among tumor-infiltrating lymphocytes from HLA-A2 + patients with breast cancer. Last, we showed that HERV-specific T cells lyse patient-derived organoids. These shared virus-like epitopes are of major interest for the development of cancer vaccines or T cell–based immunotherapies, especially in tumors with low/intermediate mutational burden.
Fichier principal
Vignette du fichier
Bonaventura et al. - 2022 - Identification of shared tumor epitopes from endog.pdf (11.8 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03552937 , version 1 (15-11-2022)

Identifiers

Cite

Paola Bonaventura, Vincent Alcazer, Virginie Mutez, Laurie Tonon, Juliette Martin, et al.. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Science Advances , 2022, 8 (4), ⟨10.1126/sciadv.abj3671⟩. ⟨hal-03552937⟩
15 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More